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Abstract
Background: The requirements for priming of HIV-specific T cell responses initially seen in infected individuals remain to be
defined. Activation of T cell responses in lymph nodes requires cell-cell contact between T cells and DCs, which can give
concurrent activation of T cells and HIV transmission.
Methodology: The study aim was to establish whether DCs pulsed with HIV-1 could prime HIV-specific T cell responses and
to characterize these responses. Both infectious and aldrithiol-2 inactivated noninfectious HIV-1 were compared to establish
efficiencies in priming and the type of responses elicited.
Findings: Our findings show that both infectious and inactivated HIV-1 pulsed DCs can prime HIV-specific responses from
naı ¨ve T cells. Responses included several CD4
+ and CD8
+ T cell epitopes shown to be recognized in vivo by acutely and
chronically infected individuals and some CD4
+ T cell epitopes not identified previously. Follow up studies of acute and
recent HIV infected samples revealed that these latter epitopes are among the earliest recognized in vivo, but the responses
are lost rapidly, presumably through activation-induced general CD4
+ T cell depletion which renders the newly activated
HIV-specific CD4
+ T cells prime targets for elimination.
Conclusion: Our studies highlight the ability of DCs to efficiently prime naı ¨ve T cells and induce a broad repertoire of HIV-
specific responses and also provide valuable insights to the pathogenesis of HIV-1 infection in vivo.
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Introduction
HIV-specific cellular immune responses play a central role in
controlling HIV-1 replication and in delaying disease progression
in infected individuals. The importance of CD4
+ and CD8
+ T cell
responses is highlighted in longterm nonprogressors (LTNPs),
whose ability to control infection is correlated with the presence of
strong and broadly directed HIV-specific T cell responses [1,2,3].
The presence of activated and proliferating CD4
+ CCR5
+ gag
specific T cells, expressing perforin and granzyme B, in early
primary infection supports a potential role for them in helping to
control viral replication [4]. However, these T cells disappear as
the infection progresses. Similar virus-specific perforin expressing
CD4
+ T cells exist in rhesus macaques infected with attenuated
strains of SIV which protected them from virulent wild type virus
challenge [5]. These studies highlight the important role T cells,
more specifically CD4
+ T cells, can play in determining the course
of infection.
Dendriticcells(DCs)arethe onlyAPCcapableofpriming naı ¨veT
cells in vivo and turning them into long-lasting functional memory T
cells. The magnitude and strength of a generated T cell response is
based on the quality of the initial priming event, which in turn
depends on several factors including trafficking of DCs to lymph
node[6] and the quality of the initial DC-T cell interaction[7].
Vaccine studies have demonstrated that it is possible to activate
alreadyexisting memorycells and prime newT cellresponses invivo
[8,9,10]. A recent study used an autologous vaccine consisting ofDC
pulsed ex vivo with AT-2 inactivated HIV-1 (AT-2 HIV-1) provided
promising data with induction of increased levels of HIV-specific T
cells and decreased viral load in chronically infected subjects[10].
PLoS ONE | www.plosone.org 1 January 2009 | Volume 4 | Issue 1 | e4256Thus, DCs appear to be central in the generation of protective
immunity against HIV-1.
Previous studies examining in vitro HIV-1 T cell priming have
used MDDCs pulsed with different HIV-antigenic constructs, such
as peptides, proteins, liposome complexed proteins and cDNA
[11,12,13,14] to prime naı ¨ve T cells. However, the capacity of
DCs pulsed with whole virions; the most physiological source of
HIV-antigens, to prime T cells in vitro has not been investigated.
Here, we examined whether infectious and AT-2 HIV-1, with
functional binding and fusion abilities, can serve as efficient
sources of antigen for DCs to prime HIV-specific T cells from
naı ¨ve cells in vitro. The use of AT-2 HIV-1 as a source of antigen
may be particularly relevant as the majority of virions found in
circulation do not possess culturable infectivity [15,16,17,18].
Even if not infectious, these viruses may serve as an important
source of antigens in vivo. Using both infectious and AT-2 HIV-1
also allowed us to compare the nature of responses generated with
these antigen sources, findings of great interest for vaccine design.
Our findings show that DCs loaded with AT-2 or infectious
HIV-1 primed HIV-specific responses from naı ¨ve T cells from
uninfected individuals in vitro. Priming with AT-2 HIV-1 yielded
slightly more frequent responses. MDDCs pulsed with HIV-1
stimulated significantly more CD4
+ than CD8
+ T cell responses.
The specificities of the primed T cells consisted of epitopes located
in env gp41 and gp120, gag p17 and p24, and pol INT and RT.
For the CD4
+ T cell responses, five out of ten of the in vitro
primed responses matched the responses seen ex vivo in HIV-
infected individuals at different stages of disease[19]. Furthermore,
we identified several novel HIV-1 CD4
+ T cell responses in env
and pol, and we were able to detected 4 out of 5 of these novel
responses in acute and recent HIV-infected individuals. The
overwhelming CD4
+ T cell responses seen in our in vitro priming
are consistent with the strong and broad CD4
+ T cell responses we
have observed in individuals with acute HIV-infection and which
disappeared or were greatly reduced within three months after
onset of infection. Although less frequent, CD8
+ T cell responses
were also observed. Of note, all in vitro primed CD8
+ T cell
responses matched the responses seen ex vivo in HIV-infected
individuals at different stages of disease [19,20]. Our study shows
that DCs pulsed with HIV-1 can prime the same responses that
arise naturally in vivo in HIV-infected individuals and demon-
strates that AT-2 HIV-1 is a excellent source of antigens that may
have the capacity in a vaccine setting, not only to restimulate
existing memory responses but also prime for new T cell responses
or re-establish responses lost very early on during infection.
Results
The aims of this study were to establish whether DCs pulsed
with infectious or chemically inactivated HIV-1 could prime HIV-
specific T cell responses, examine the quality of primed T cell
responses, and compare them with the responses observed in vivo
in primary HIV-infection. Infectious and noninfectious (AT-2
HIV-1) virions of HIV-1MN, were tested side by side to evaluate
priming efficiency and qualitative characteristics of the T cell
responses elicited. HIV-1 specific priming was performed using
MDDCs and naı ¨ve CD45RA
+ CD62L
+ bulk T cells from PBMCs
from 11 HIV-negative individuals.
Exposure of mature MDDCs to AT-2 or infectious HIV-1
does not reverse their phenotypic and functional
maturation
The contact between the virus and DC subpopulations likely
represents a fundamental part of HIV-1 pathogenesis and may
affect the DCs phenotype and ability to stimulate T cells
[21,22,23,24]. To evaluate potential deleterious effects of HIV-1
exposure on the antigen presenting properties of DCs to be used
for T cell priming, we assessed the effect of HIV-1 on the viability
and expression of costimulatory molecules of matured MDDC
after overnight incubation with AT-2 or infectious HIV-1MN.A t
the dosage of virus used in the subsequent experiments, 150ng p24
equivalent/10
5 cells, we did not observe any negative effect on the
viability (data not shown), maturation status (Figure 1A) or ability
to activate HIV-specific T cell clones (Figure 1B). Furthermore,
the ability of MDDCs pulsed with either infectious or AT-2 HIV-1
to activate and expand CD4
+ and CD8
+ HIV-specific T cells from
chronic HIV-infected individuals was examined and DCs pulsed
with either form of virus expanded broad HIV-1 specific memory
T cell responses targeting major HIV antigens gag, pol, env, and
nef (Figure 1C and Larsson et al[25]). Additionally, our previous
study established that both forms of virus are processed and
presented in a similar manner using, for the most part, the classical
pathways for MHC class I and II presentation [26]. These findings
establish that the ability of DCs to function as APCs is preserved in
this system, both for infectious and AT-2 HIV-1.
Both infectious and AT-2 inactivated HIV-1 can be used
as antigenic sources by DCs to prime HIV-specific T cells
from CD45RA+ naı ¨ve T cells
The ability of DCs to prime HIV-specific responses in vitro has
previously been established by several studies using various antigen
preparations, e.g. peptides, proteins, liposome complexed proteins
and cDNA[11,12,13,14] but not whole virions, the most physio-
logically relevant source of HIV-antigens. We tested whether we
could prime HIV-specificT cells invitro using an autologous system
consisting of mature DC, pulsed with AT-2 or infectious HIV-1,
and naı ¨ve CD45RA
+ CD62L
+ bulk T cells (Figure 2A) from
uninfected individuals. HIV-priming was usually achieved after the
third or fourth restimulation, as measured by intracellular IFN-c
staining after antigenic rechallenge, (Figure 2B) and considered
positive when the level of responding cells, i.e. IFN-c producing T
cells, was .1%–5% above the non-specific IFN-c production.
Priming was achieved in 8 out of the 11 donors examined
(Figure 2C), and reasons for the failure to induce priming in all
donors are unknown, but may include the death of newly activated
T cells,theHLA differences amongdonors,oreven T cellimpairing
effects exerted by the virus on the immune cells from some
individuals. Cultures using unpulsed DCs served as controls for the
specificity of the HIV-priming assays and no significant HIV-
specific responses were observed in these mock-primed cultures
(Figure 2B). Of note, we observed a background production of
cytokines when the HIV-1 primed T cells were tested with unpulsed
DCs and this is attributed to T cells still active from the weekly
restimulation with HIV-1 pulsed DC as the culture with mock DC
did not have this production.
We have shown equivalent efficiency of MDDCs to process and
present antigens derived from AT-2 HIV-1 or infectious HIV-1 as
measured by activating HIV-specific memory T cells from chronic
HIV infected individuals[27] (Figure 1C). However, as the
source of antigens for the in vitro priming of naı ¨ve T cells by
MDDCs, AT-2 HIV-1 was slightly more efficient, 59% of all
primed responses was achieved using AT-2 HIV-1 compared to
41% by its infectious counterpart (Figure 2D). This outcome
may be attributed to negative immune regulatory effects exerted
by infectious HIV-1 on newly activated T cells and/or effects on
the DCs in these long term cultures [24,28,29]. Of note, we
observed low levels of replication in the priming cultures with
infectious HIV compared to priming cultures with AT2-HIV
HIV Specific T Cell Priming
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PLoS ONE | www.plosone.org 3 January 2009 | Volume 4 | Issue 1 | e4256(Figure 2E). Our study demonstrates for the first time that HIV-1
pulsed DCs can prime HIV-specific T cells from naı ¨ve donors and
that AT-2 inactivated HIV-1 was slightly more efficient than
infectious HIV-1 as an antigenic source.
DCs pulsed with infectious or AT-2 HIV-1 primed
polyfunctional T cell responses that target a broad
repertoire of HIV-antigens
The requirement for initiation and maintenance of broad and
strong T cell responses capable of controlling viral load is clear
when examining the HIV-infected individuals that do succeed to
control the virus for many years [1]. To establish the antigenic
repertoire of the primed T cells, the HIV specific polyclonal T
cell populations were evaluated by IFN-c E l i s p o tu s i n gas e to f
overlapping peptides spanning the complete HIV Clade B
consensus sequence (Figure 3A). We found broad responses
targeting epitopes located in gag MA (15%), CA (8%), pol INT
(22%), RT (15%), env gp120 (10%) and gp41 (8%) (Figure 3 B,
Table 1).I nm o s tc a s e s ,p r i m e dTc e l l sf r o mv a r i o u sd o n o r s
recognized as few as two epitopes or as many as nine. For
instance, the specific responses we detected in donor MP880
were located in env gp41, env gp120, gag MA (p17), gag CA
(p24) and pol INT, thus demonstrating that within one donor a
broad repertoire of HIV-specific T cell responses can be primed
using MDDCs.
We examined if the HIV-1 specific polyclonal cell lines, selected
based on the production of IFN-c, had the ability to produce other
effector cytokines such as IL-2, TNF-a or MIP-1b when stimulated
with MDDCs exposed to HIV-1 (Figure 3C). The HIV-specific
CD4
+ T cells (Figure 3D) and CD8
+ T cells (Figure 3E) in the
polyclonal population were found to produce one to four cytokines
upon stimulation. Taken together, these findings demonstrate that
the primed CD4
+ and CD8
+ T cells target a broad repertoire of
HIV-1 antigens and that they are polyfunctional in their ability to
secrete multiple cytokines upon stimulation.
The responses most frequently detected in HIV-1 infected
individuals, independent of the stage of the disease, are gag p24-
and nef-specific T cells[30]. Besides yielding the highest frequency
of HIV-specific T cells, these two proteins also contain the highest
epitope density [20,30]. Our in vitro priming induced a variety of
p24-specific responses and they constituted 22% of all HIV-1
specific responses primed. However, in contrast to Addo et al [30]
no nef specific responses were confirmed in our assays. The reason
for this discrepancy between the in vivo and the in vitro responses
is unclear. However, we can rule out the possibility that the DCs
are unable to process and present the nef protein as we have
previously shown that DCs can activate nef specific memory T
Figure 2. HIV-1 pulsed MDDCs prime HIV-1 specific T cells. (A) Autologous naı ¨ve bulk (CD4
+ and CD8
+) T cells were negatively isolated from
PBMCs by magnetic beads to remove CD14, CD19, CD56 and CD45RO positive cells. (B) The autologous naı ¨ve bulk T cells were co-cultured with the
mock (no virus), AT-2 or infectious HIV-pulsed DCs. Cultures were restimulated weekly by the addition of DCs pulsed with mock, AT-2 HIV-1 or Inf HIV-
1 for 4 weeks. HIV-specific responses were detected by intracellular cytokine staining for IFN-c after 4 weeks of culture. (C) HIV-1 specific priming was
attempted with bulk T cells from 11 HIV naı ¨ve donors to establish the efficiency of in vitro MDDC priming. 8 out of 11 donors were successfully
primed. (D) The priming efficiency of MDDCs pulsed with AT-2 HIV-1 vs. infectious HIV-1 of the 8 donors that was successfully primed were compared.
(E) Priming cultures were analyzed for the presence of viral replication. Supernatants were collected from the cultures after the 3
rd restimulation on
day 21 and virus replication was measured using HIV p24 ELISA kit. Mock, AT2-HIV, and Inf HIV priming cultures were compared.
doi:10.1371/journal.pone.0004256.g002
HIV Specific T Cell Priming
PLoS ONE | www.plosone.org 4 January 2009 | Volume 4 | Issue 1 | e4256cells when pulsed with HIV-1 (Figure 1C)[25]. Alternatively, the
lack of nef responses may be attributed to lack of viral replication
within the priming cultures. Relatively little nef is found in virions
and in the absence of robust productive infection, there may be
insufficient antigen available for priming, particularly compared to
more abundant proteins like gag, pol, and env.
The specificity of the in vitro primed T cell responses
reflect those seen in infected individuals primed in vivo
Several studies have analyzed the specificity of HIV-1 memory
T cell responses existing in infected subjects by ex vivo assays
[19,31,32] and the CD8
+ T cells are so far the most extensively
studied [32,33]. Less is known about HIV-specific CD4
+ T cells as
these are specifically targeted by the virus as the infection
progresses [34,35]. The majority (86%) of the confirmed primed
responses were CD4
+ T cells (Figure 4A). The basis for this
CD4
+ skewing could be attributed to several factors including use
of whole virions as the source of antigens, and the in vitro system
used for delivery of the virus. In addition, CD4
+ T cell responses
are the first to arise in vitro and may thus overwhelm the CD8
+ T
cells. However, we can rule out the possibility that our in vitro
system merely selects for the development of HIV-specific CD4
+ T
cells. Though they made up a minority of the responses observed,
we did see unequivocal development of HIV-specific CD8
+ T cells.
Furthermore, when we depleted CD4
+ T cells from the co-culture
system, we saw enhancement of priming of CD8
+ T cells
(Figure 4C). Therefore, it is possible to prime HIV-specific
CD8
+ T cells using our in vitro system.
Figure 3. HIV-specific T cells are polyfunctional and recognized a broad repertoire of antigens. (A) Mapping of epitopes was done using
pools of overlapping peptides. The peptides spanned the entire HIV-1 genome and were based on the consensus B sequence (http://www.hiv.lanl.
gov/content/immunology/index.html). The peptide pool matrices and the HIV-1 primed T cell cultures were added to IFN-c Elispot assays as
described previously [19]. The assays were developed after overnight culture and evaluated. Reconfirmations of all positive wells were done the
following day with the single peptide by flow cytometry to detect intracellular IFNc production. (B) The reconfirmed HIV-1 specific T cell responses
from all donors tested were analyzed to determine which HIV-1 antigens the primed T cells recognized and the percentile they constituted of total
primed responses from those screened. (C) The effector functions of the HIV-1 specific polyclonal T cells were examined by stimulation with MDDCs
pulsed with AT-2 HIV-1 or infectious HIV-1 and the intracellular production of the effector cytokines/chemokines; IFN-c, TNF-a, IL-2 and MIP-1b, was
measured by flow cytometry. The polyfunctionality of the T cell responses were analyzed as the ability to produce the combination of one, two, three
or all four of the cytokines/chemokines tested by the primed CD4
+ (D) and CD8
+ (E) T cells in response to HIV.
doi:10.1371/journal.pone.0004256.g003
HIV Specific T Cell Priming
PLoS ONE | www.plosone.org 5 January 2009 | Volume 4 | Issue 1 | e4256In our in vitro priming, five out of ten CD4
+ T cell responses
matched the responses previously documented ex vivo with cells
from HIV-1 infected subjects at different stages of disease and a
number of these HIV-1 specific CD4
+ T cell responses are
frequently detected (Table 2: Figure 4B)[19]. The primed p24
epitopes WIILGLNKIVRMYSPTSI and YVDRFYKTLRAE-
QASQEV are frequently observed in HIV-infected sub-
jects[19,30] and p24 contains several CD4
+ T cell epitopes[19].
For instance, the WIILGLNKIVRMYSPTSI p24133-150 response
was frequently seen in the majority of the donors we tested and
several T cell clones responding to epitope/s located within p24
have been established (data not shown). p24133-150 is contained
within the immunodominant region of gag and also contains
several known CD8-epitopes including GLNKIVRMY and
IILGLNKIVR. Moreover it contains multiple CD4+ epitopes
that are promiscuous and can be loaded on to several different
HLA DR haplotypes (e.g. ILGLNKIVRMY recognized in
DRB1*0101, DRB1*1302, DRB1*1501) a factor that may
contribute to its frequent recognition. In addition, the peptide
YVDRFYKTLRAEQASQEV has been reported to be the
peptide most recognized by CD4
+ T cells in all categories of
subjects investigated[19].
Studies on the antigenic specificity of CD8+ T cell responses in
HIV-1 infected subjects, especially in chronic infection, are more
comprehensive [31,32]. Responses to three in vivo HIV-1 specific
CD8
+ T cell epitopes described in HIV-1 infected patients were
primed in our in vitro system and all were gag specific. They are
located within gag p15 and p17, corresponding to TGSEELR-
SLYNTVATL p1770-85 and SGGELDRWEKIRLRPGGK p179-
26 and RNQRKIVKCFNCGKEGHT p1521-38 (Table 2). These
peptides contain at least five epitopes that have been identified ex
vivo in HIV-1 infected subjects at different stages of disease
[19,31,36] (Los Alamos NL). CD8
+ T cells specific for the
TGSEELRSLYNTVATL and SGGELDRWEKIRLRPGGK
p17 epitopes have also previously been primed for in vitro using
DCs pulsed with liposome complexed HIV-1 protein[11] and DC
pulsed with peptide[12]. The CD8
+ T cell responses primed with
peptide pulsed DCs recognized the epitope KIRLRPGGK within
the p17 SGGELDRWEKIRLRPGGK sequence and this is a
HLA*A3-restricted epitope[12]. Our response was seen in a HLA*
A3-positive subject and thus could be directed to the same CD8
+
T cell epitope. Alternatively, it could be a novel epitope response
contained within the same region. Thus comparison of our data
with ex vivo data obtained from HIV-infected subjects demon-
strates that the epitopes seen in our in vitro priming correlates with
T cell responses that develop in vivo.
Strong and broad HIV-specific CD4 T cell responses can
be identified at time of acute HIV-infection but quickly
decline irrespective of treatment status
The predominantly CD4
+ T cell responses and the observation
of in vitro primed specificities that had not been previously
reported from studies of infected patients prompted us to re-
examine in vivo responses more closely, in particular in acute
HIV-infected subjects. In order to assess the repertoire of HIV-
specific CD4
+ T cell responses found in acute HIV infection
(AHI), we used fresh CD8-depleted PBMCs from 12 subjects with
documented AHI and screened them for HIV-specific CD4
+ T
cell responses. Peptides were divided in peptide pools correspond-
ing to the different HIV proteins before being used in the Elispot
assays and responses were analyzed per protein and as total
response obtained by summing up the responses to the individual
HIV proteins. Furthermore, we monitored changes in CD4
+ T cell
responses over time. At the first available time point for
immunological studies and before initiation of HAART (baseline,
BL), all investigated subjects showed a positive, and in most cases
robust, HIV-specific CD4
+ T cell response (median total response
2,780 SFC/10
6 CD8-depleted PBMCs; range 315-8646)
(Figure 5A). At one month after BL, 8 out of 9 evaluated subjects
showed a decrease in magnitude of the HIV-specific CD4
+ Tc e l l
responses compared to baseline (p=0.02; Wilcoxon matched pairs
test)Further decline was observed 3 months after BL compared to
the one month time point in 6 of 7 individuals studied longitudinally
(p=0.04; Wilcoxon matched pairs test). The HIV-specific CD4
+ T
cell responses waned in both subjects treated with HAART (grey
circles) and in individuals who remained without therapy (white
circles) and occurred while most subjects were still viremic, showing
thatthe reductioninHIV-specificCD4
+T cell responsesoccurredin
spite of a continuous exposure to the antigen.
In order to investigate the responses to the different proteins, we
next analyzed the evolution of the CD4
+ T cell responses to the Gag,
Pol, Env and Nef proteins (Figure 5B). The results demonstrate
Table 1. Primed CD4 and CD8 T cell responses
Polyclonal T cell
Lines Virus Protein OLP Sequence
BS874 AT2 #19 MN AT2 gag/p24 WIILGLNKIVRMYSPTSI
BS874 AT2 #21 MN AT2 gag/p17 TGSEELRSLYNTVATL
BS874 AT2 #23 MN AT2 gag/p24 WIILGLNKIVRMYSPTSI
BS874 AT2 #24 MN AT2 gag/p24 WIILGLNKIVRMYSPTSI
YVDRFYKTLRAEQASQEV
BS874 AT2 #25 MN AT2 gag/p24 WIILGLNKIVRMYSPTSI
BS874 LHIV #14 MN LHIV gag/p24 WIILGLNKIVRMYSPTSI
pol/RT MTKILEPFRRKQNPDIVIY
BS874 LHIV #17 MN LHIV gag/p24 WIILGLNKIVRMYSPTSI
pol/RT MTKILEPFRRKQNPDIVIY
BS874 LHIV #35 MN LHIV gag/p15 RNQRKIVKCFNCGKEGHT
MP980 LHIV #9 MNLHIV gag/p17 TGSEELRSLYNTVATL
MP980 LHIV #16 MN LHIV pol/INT ELKKIIGQVRDQAEHLK
MP980 AT2 #7 MN AT2 env/gp41 LELDKWASLWNFDITN
gag/p17 KHIVWASRELERFAV
MP980 AT2 #9 MN AT2 gag/p24 WIILGLNKIVRMYSPTSI
MP980 AT2 #36 MN AT2 env/gp41 AVLSIVNRVRQGYSPLSE
env/gp120 RPVVSTQLLLNGLSLA
MP980 AT2 #48 MN AT2 gag/p17 SGGELDRWEKIRLRPGGK
DR682 AT2 #1 MN AT2 pol/INT TKELQKQITKIQNFRVYY
gag/p24 IVQNLQGQMVHQAISPR
DR682 AT2 #3 MN AT2 gag/p17 IVQNLQGQMVHQAISPR
pol/INT AYFLLKLAGRWPVKTIH
LKTAVQMAVFIHNFKRK
DR682 AT2 #5 MN AT2 gag/p24 WIILGLNKIVRMYSPTSI
DR682 AT2 #7 MN AT2 env/gp41 LELDKWASLWNFDITN
JP651 LHIV #13 MN LHIV gag/p24 IVQNLQGQMVHQAISPR
gag/p15 HIAKNCRAPRKKGCWK
EW836 LHIV #5 MN LHIV pol/RT YELHPDKWTVQPIVLPEK
EW836 AT2 #4 MN AT2 gag/p17 LEKIEEEQNKSKKKAQQA
JN521 AT2 #1 MN AT2 gag/p15 GKIWPSHKGRPGNFLQSR
gag/p17 MGARASVLSGGELDRWEK
doi:10.1371/journal.pone.0004256.t001
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+ T cell responses at the time of acute
infection target various proteins and that the overall responses
declined over time. Gag-specific responses remained detectable six
months after AHI whereas most subjects had lost their Pol-, Nef-,
and Env-specificresponses atthistimepoint.Of note, the magnitude
of Env-specific CD4
+ T cell responses detectable during AHI is
remarkable compared to their rarity in chronic infection [37]. We
used intracellular cytokine staining for IFN-c and IL-2 to confirm
this decline in HIV-specific CD4
+ T cell responses after AHI with
another experimental approach (Figure 5C). The strong IFNc-
and IL-2 HIV-Gag-specific CD4
+ T cell response present at baseline
before institution of therapy declined over time, contrasting with the
stability of the CMV- specific CD4
+ T cell response, demonstrating
that this phenomenon is HIV-specific. Thus, robust and broad HIV-
specificCD4
+ T cellresponses can be detected during AHI however,
they quickly decline. In particular, Env-specific CD4
+ Tc e l l
responses, which are not commonly detected in chronic HIV-
infected subjects, are readily detected during AHI. However, these
responses disappear very quickly. Therefore, the CD4
+ Tc e l l
responses we saw in our priming could be a reflection of what is
happening during acute infection whereby broad HIV-1 specific
CD4
+ T cell responses are activated very early on, even before the
development of HIV-specific CD8
+ T cells and decline as activated
CD4
+ T cells are directly or indirectly destroyed by the virus.
Novel epitopes primed for in vitro correlated with CD4
responses that arise and are present during acute and
recent HIV-1 infection
Our findings that the CD4
+ T cell responses decline rapidly in
acute HIV-infected subjects could explain why several of the
CD4
+ T cell responses we succeeded to prime for in vitro have not
previously been described in the literature. The novel HIV-1 T
cell responses we found in env and pol are contained within
peptides ELKKIIGQVRDQAEHLK in pol IN157-173, MTKI-
LEPFRKQNPDIVIY in pol RT163-181, AVLSIVNRVRQ-
GYSPLSF env gp41700-717, LELDKWASLWNWFNITNW in
env gp41601-678, and RPVVSTQLLLNGSLA in env gp120252-266.
The ELKKIIGQVRDQAEHLK in pol IN, MTKI-
LEPFRKQNPDIVIY in pol RT and AVLSIVNRVRQGYSPLSF
env gp41 have so far been found in only 1 out of 36 chronic HIV
infected subjects tested (data not shown). In addition, screening
of acute and recent HIV-infected subjects revealed that CD4
+
responses to 3 of 5 novel epitopes within pol and env are readily
detected. We have been able to confirm CD4
+ T cell responses to
Figure 4. The majority of the responses primed by MDDCs are HIV-1 specific CD4+ T cell responses. (A) The HIV-1 specific T cell
responses from all donors tested were characterized for expression of CD4 or CD8 and plotted as the percentile of total confirmed primed responses.
(B). Single peptide confirmation of HIV-1 specific T cells were done with the specific peptide by flow cytometry to detect intracellular IFNc production.
The dot plots shows HIV-1 specific CD4
+ T cell responses for gag OLP 37, gp41 OLP 377 and gp41 OLP 382. (C) HIV-1 specific priming of CD8
+ T cells.
CD8
+ T cells were obtained by flow cytometry sorting. After the 4th restimulation, HIV-specific responses were detected by intracellular cytokine
staining for IFN-c.
doi:10.1371/journal.pone.0004256.g004
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pol IN157-173, RPVVSTQLLLNGSLA in env gp120252-266, and
AVLSIVNRVRQGYSPLSF in env gp41700-717 (Figure 6A)
when we screened subjects directly ex vivo that were HIV-1 infected
less than 6 months. We were unable to confirm more of our novel
epitopes in more HIV-infected subjects due to the fragile nature of
CD4
+ T cells at this early time point of infection and difficulty of
obtaining enough CD4
+ T cells from acute HIV-infected subjects.
WithoneacuteHIV-infectedsubjectfromwhomwereceivedfollow-
upsamples,wedetectedCD4
+Tcellresponsestoepitopescontained
within peptide AVLSIVNRVRQGYSPLSF in env gp41700-717 at
the initial time point however, screening of PBMCs from subsequent
time points revealed the rise and decline of responses targeting
epitopeswithin this particular peptide (Figure 6B).N o n e t h e l e s s ,w e
provide evidence that novel epitopes seen in our in vitro priming
may represent T cell responses seen in AHI that disappear in the
infected individuals so early on that they are gone in most individual
at time of their HIV-1 diagnosis.
Taken together, our data establishes that MDDCs presenting
either infectious or AT-2 HIV-1 derived antigens can prime
polyfunctional CD4
+ and CD8
+ HIV specific T cells that target a
broad repertoire of HIV-antigens. Furthermore, we show that our
primed HIV-specific T cells correlate to T cells that arise naturally
in vivo in HIV-1 infected individuals, more specifically during
AHI and is lost early on. Though noninfectious HIV-1 had slightly
higher efficiency in priming, there were no significant differences
in terms of the type of responses elicited thus demonstrating that
defective viruses, can serve as a source of antigen in vivo.
Discussion
The cellular immune response developed against HIV-1 is
multifaceted. DCs in the lymph nodes probably contribute both to
the initial strong T cell responses and at the same time to the defects
seen in CD4
+ T cells during AHI. One mechanism explaining the
efficiency of viral spread is the formation of the infectious synapse
whereby DC harboring HIV-1 interacts with T cells [28,38]. In this
setting, the activated HIV-specific CD4
+ T cell, expressing CCR5
and high levels of CD38, are prime targets for infection in vivo
during primary HIV-infection[39], which explains the preferential
infection of HIV-1 specific CD4
+ Tc e l l s [ 3 5 ] .
The HIV-1 specific CD4
+ T cells rapidly decline two and three
weeks following the onset of the acute viral illness. This may
depend on that 80–90% of these cells lack CD127 during primary
HIV-infection, consistent with a predetermined apoptotic fate
[39]. In spite of the rapid loss initially, HIV-1 specific CD4
+ T cells
do persist in individuals at all stages of HIV-infection and comprise
from 0.02%–2% of the peripheral blood CD4
+ T cells. The
majority of the CD4
+ T cells that remain in individuals with
persistent viremia have defective proliferation ability due to
impaired development of IL-2 producing TCM cells [40], PD-1
and CTLA-4 expression [29,41].
While the exact proportions of infectious and non-infectious virus
circulating in vivo remain the subject of some controversy. The role
of these noninfectious virions as antigen for priming immune
responses has not been explored. Therapeutic vaccination of SIV-
infected rhesus monkeys [42,43] and chronically HIV-infected
subjects[10] with autologous DCs pulsed with AT2-inactivated virus
was associated with reduced viral loads and enhancement of HIV-
specific immune responses. Therefore, we hypothesized that DCs
may also have the capacity to present antigens from fusion
competent nonreplicating virus i.e. AT-2 HIV-1[25,44] to prime
HIV-specific T cell responses. Here we show for the first time that
AT-2 HIV-1 can serve as an efficient source of antigen for priming
both CD4
+ and CD8
+ T cells and therefore function as a relevant
source of antigen for priming in vivo.
The continuous presence of viral antigens gives rise to new
memory T cells from the existing naı ¨ve population as long as the
immune system remains functionally intact and/or the existing
naı ¨ve T cells can respond to HIV-antigens [45] thus explaining the
highly heterogeneous population of HIV-specific T cells that exist
Table 2. Correlation of primed T cell responses with in vivo data
Tc e l l
Type HIV Protein HXB2 location OLP sequence Epitopes (HLA-restriction)
Stage of
disease References
CD4 Gag p17 9–26 SGGELDRWEKIRLRPGGK Human Mostly in acute
Lower responses
in chronic High
responses in
untreated
&Kaufmann et al J Virology
2004
CD4 Gag p17 32–46 KHIVWASRELERFAV Human &Wilson et al J Virology 2001
CD4 Gag p17 70–86 TGSEELRSLYNTVATLY Human &Los Alamos HIV Immunology
Database
CD4 Gag p24 133–150 WILLGLNKIVRMYSPTSI* DRB1*1501, DRB1*1302, DRB1*0401,
DRB5*0101, DRB1*1101, DRB1*0701,
DRB1*0405, DRB1*0101
CD4 Gag p24 164–181 YVDRFYKTLRAEQASQEV DRB1*1501, DRB1*1302, DRB1*0401,
DRB5*0101, DRB1*1101, DRB1*0701,
DRB1*0405, DRB1*0101
CD4 Pol INT 210–277 TEKLQKQITKIQNFRVYY Human, DR supermotif
CD8 Gag p17 9–26 SGGELDRWEKIRLRPGGK A* 0301, A3, B*4002, B7, B27,
B40, B63
Found in all
stages of disease
&Addo et al J Virology 2001
&Frahm et al J Virology 2005
CD8 Gag p17 70–85 TGSEELRSLYNTVATL A*0101, A1, A2, A*0201, A*0202,
A*0205, A*0214, A24, B*4006, B*0801,
B8
&Los Alamos HIV Immunology
Database
doi:10.1371/journal.pone.0004256.t002
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cell responses that we observed were CD4
+ T helper cells
recognizing epitopes within Env (gp120
SU, gp41
TM, p24
CA,
p17
MA), and Pol (RT and IN). The majority of the CD4
+ T cell
responses and all of the CD8
+ T cell responses we observed in our
priming targeted the same antigenic regions that had previously
been documented in acutely and/or chronically HIV-infected
subjects[19,31,36,46,47]. Individuals with acute or long term
nonprogressive infection have a strong HIV-specific T cell ex vivo
proliferative capacity, whereas this effector function seems to be
absent in chronically infected individuals with high level of viremia
[1,2,3]. The changes in functionality and phenotype of HIV-
specific CD4
+ T cells are a consequence of high levels of antigens
[40]. The persistence of CD4
+ T cells with defective proliferation
suggests a dysfunction possibly due to impaired development of IL-
2 producing central memory T cells [48,49]. In contrast, the T
cells activated in our in vitro priming are polyfunctional memory
T cells, capable of secreting IL-2, IFN-c, MIP-1b and TNF-a in
response to stimulation. In addition, the HIV-specific T cells had
the ability to recognize and proliferate in response to stimulation
with both infectious and AT-2 HIV-1.
A number of the in vitro primed CD4
+ T cell responses were
towards peptides that had not previously been documented to
elicit responses in the studies of infected individuals. When we
investigated a cohort of acute/recent HIV-infected subjects, we
detected responses to 4 of the 5 novel epitopes within env and pol
that we found in our in vitro priming. Novel CD4
+ T cell
responses to the env gp41 peptides AVLSIVNRVRQGYSPLSF
and LELDKWASLWNWFNITNW were seen in a couple of the
donors used for priming. When we re-examined the CD4
+ T cell
responses of acute HIV-infected subjects for responses against
these epitopes we were able to detect responses targeting the
AVLSIVNRVRQGYSPLSF peptide. However, CD4
+ T cell
responses against this epitope waned as the infection progressed
Figure 5. Strong and broad HIV-specific CD4 T cell responses exist in acute infection which quickly diminish. (A and B) Fresh CD8-
depleted PBMCs from 12 adult individuals with documented primary HIV infection (PHI) were screened for HIV Gag-specific CD4 responses by IFNc
Elispot using a pool of overlapping peptides spanning all HIV proteins and corresponding to Clade B consensus sequence 2001. Subjects were
assessed at baseline (BL) before institution of any antiviral therapy and 1 month, 3 months and 6 months after BL. Data represent total HIV-specific
CD4 T cells responses (A) as well as responses to individual gene products (B). Grey circles: subjects treated with HAART; white circles: individuals who
remained without therapy. Horizontal black bars: median values. (C) This decline can also be demonstrated by intracellular cytokine staining and
affects both IFNc- and IL-2-secreting CD4+ T cells. Fresh PBMCs from an adult individual with acute HIV infection were stimulated with medium alone,
the same HIV Gag as above or a CMV lysate, in the presence of anti-CD28 and anti-CD49 stimulating antibodies and submitted to intracellular
cytokine staining after six hour incubation. Similar experiments were performed 12, 24 and 36 weeks after BL. These results are representative of
three separate subjects. Numbers in quadrants: percentage of cytokine-producing CD4
+ T cells.
doi:10.1371/journal.pone.0004256.g005
HIV Specific T Cell Priming
PLoS ONE | www.plosone.org 9 January 2009 | Volume 4 | Issue 1 | e4256and were no longer detected at later time points. We have only
observed a persisting response to this peptide in one subject that
was chronically HIV-infected (data not shown).
On the other hand, CD4
+ T cell responses to the peptide
LELDKWASLWNWFNITNW env gp41601-678 so far remain
undetected in acute and chronic HIV-1 infected subjects studied
by our group and others (data not shown[19,31,36]). Interestingly,
LELDKWASLWNWFNITNW corresponds to a highly conserved
membrane proximal region of the gp41 and is only exposed during
the fusion of the virus with the host membrane[50]. This epitope
lies within a region identified as a CD4-epitope ‘‘hotspot’’ in mice
immunized with HIV gp120[51], consistent with the idea that an
otherwise immunodominant specificity is selectively eliminated in
HIV-infected humans. Of note, this particular peptide also
contains epitopes of two broadly neutralizing HIV-1 antibodies
(2F5 and 4E10) that have been shown to be polyspecific
autoantibodies reactive to phospolipid cardiolipin [52] Thus our
inability to confirm responses to this particular peptide in HIV-
infected subjects may be in part due to its autoimmune nature.
To further understand the skewing of priming to CD4
+ T cells,
we decided to examine CD4
+ T cell responses in acute HIV-
infected subjects. Our studies reveal that broad and strong CD4
+
T cell responses are readily detected during AHI although some
responses vanished within 1–2 months. Of note, CD4
+ T cell
responses targeting env are strong during this early stage and are
detected as early as five days post-infection, whereas env responses
are rarely detected in the later stages of infection[53,54]. The
mechanistic basis for the apparent preferential disappearance of
HIV-specific CD4
+ T cell responses of some specificities but not
others, despite the ongoing presence of the relevant antigens, is
unclear. In the case of HIV-specific CD8
+ T cell responses there is
also evidence of rapid disappearance of initially expanded cells
and high avidity cells during AHI [55,56]. This could be
attributed to several mechanisms including mutations in the viral
genome, inhibition of the presentation and processing of certain
epitopes, and/or the inability of the T cells to adequately respond
to survival signals. In the case for HIV-specific CD4
+ T cells, an
intriguing possibility is that these particular HIV-specific CD4
+ T
cells may be specifically targeted for deletion by the virus. In fact,
we (Figure 5B and 5C) and others [34,35] do provide
convincing evidence for this particular theory. Of note, the
activation of HIV-specific CD4
+ T cell responses coincides with
the presence of a widespread activation-induced CD4
+ T cell
apoptosis so that it is possible that these newly activated HIV-
specific CD4
+ T cell responses would be eliminated as a
consequence of both specific and unspecific mechanisms.
Alternatively, loss of HIV-1 specific CD4
+ T cells may also be a
consequence of chronic immune activation, e.g. due to bacterial
translocation [57]. Regardless of the rationale, disappearance of
these HIV-specific CD4
+ and CD8
+ T cell responses during AHI
may ultimately contribute to the eventual inability of the immune
system to control viral replication. In contrast, the persistence of
HIV specific CD4
+ T cells in untreated LTNPs highlights the
importance of these cells. The helper activities of antigen-specific
CD4
+ T cells have been shown to mediate the control of many
viral infections and are critical in maintaining HIV-1 suppres-
sion[1,3,58]. However there is individual heterogeneity in
adaptive immune responses among LTNPs and consequently
the correlates of immunity remain unknown. Therefore the key to
deciphering this mystery may lie with the answer to why these
HIV-specific CD4
+ and CD8
+ T cell responses disappear during
acute HIV-1 infection [59].
In summary, our in vitro studies highlight the ability of DCs to
efficiently prime naı ¨ve T cells and induce a broad repertoire of
CD4
+ T cells. Our findings provide important evidence showing
that in a vaccine setting, AT-2 HIV-1 can not only restimulate
memory T cell responses but is also capable of priming broad and
polyfunctional de novo T cell responses. And given the recent
failure of the Merck STEP Trial [60], the need to explore
alternative vaccine platforms such as the therapeutic use of DC
pulsed with AT2-HIV becomes critical in attaining the ultimate
goal of an HIV vaccine.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Figure 6. In vitro primed novel HIV epitopes correlates with CD4
+ T cell responses seen during primary infection. (A) Summary of
responses to the novel epitopes detected in 12 acute and recent HIV-infected subject PBMCs. PBMCs from acute and recent HIV infected individuals
were thawed and tested directly ex vivo for reactivity to OLPs 11, 189, 262, 322, 377, and 382 using intracellular staining for IFN-c, TNF-a, and IL-2
after six hour incubation. Reactivity against the peptide was determined when the percentage of cytokine-secreting cells were at least twice the
percentage of cytokine-secreting cells in the unstimulated wells. (B) HIV-infected PBMCs from one donor evaluated at 3 different time points after
infection (sample one: 2 weeks after onset of retroviral syndrome: acute infection, sample two: 1 year infected: recent infection, and sample three:
2 years infected: chronic infection) were thawed and cocultured with peptide pools OLP 371-381 or OLP 382-392 for 14 days. The peptide activated
PBMCs were then assessed for reactivity to each of the individual peptides in the pools used.
doi:10.1371/journal.pone.0004256.g006
HIV Specific T Cell Priming
PLoS ONE | www.plosone.org 10 January 2009 | Volume 4 | Issue 1 | e4256Institutional Review Board of Massachusetts General Hospital and
the Fenway Community Heath Care Center, Boston or via Center
for HIV/AIDS Vaccine Immunology (CHAVI) clinical sites . All
patients provided written informed consent for the collection of
samples and subsequent analysis.
Culture medium, cytokines, and reagents
Culture medium RPMI 1640 (Mediatech, Herndon, VA) or
Yssel’s T cell medium (Gemini Bio-Products, Sacramento, CA)
was supplemented with 20ug/ml gentamicin (Gibco BRL,
Gaithersburg, MD) and 1mM HEPES (Mediatech), and 1%
human plasma or 5% PHS (Valley Biomedical, Winchester, VA).
rhGM-CSF (Immunex, Seattle, WA) and rhIL-4 (R&D Systems,
Minneapolis, MN) were obtained for the generation of DCs. rhIL-
12, rhIL-6, and rhIL-7 (R&D Systems) and rhIL-2 (Chiron Corp,
Emeryville, CA) were purchased for the priming cultures.
Dendritic cells
Leukopacks were purchased from BRT Laboratories, Inc.
(Baltimore, MD) Donors were tested prior to their initial donation
and again at each donation for the presence antibodies to HBV,
HCV, HTLV-I and II, HIV-1/HIV-2 and syphilis. PBMCs were
separated by density gradient centrifugation on Ficoll-Hypaque
(Amersham Pharmacia Biotech, Piscataway, NJ) DCs were grown
from adherent PBMCs supplemented with 300U/ml IL-4 and
100IU/ml GM-CSF. After five days, immature DCs were
collected, transferred to new plates, and induced to mature by
adding a cocktail consisting of 150ng/ml IL-6, 5ng/ml TNF, and
5ng/ml IL-1b (R&D Systems) and 1 mg/ml PGE2 (Sigma).
Viruses and infection of cells
Virions of HIV-1MN (X4-tropic), clade B were produced by
infection of CL.4/CEMX174 (T1) cells and purified by sucrose
gradient ultracentrifugation as described previously[61]. Samples
were titrated for the presence of infectious virus using AA2CL.1
cells and HIV-1 p24 antigen capture kits (AVP, NCI). Aldrithiol-2
(AT-2)-inactivated HIV-1 (AT-2 HIV) was prepared as described
previously[62]. Used in this study include infectious HIV-1MN
(Lots 3807, 3966, and 3941: AVP, SAIC Frederick, Inc., NCI
Frederick) and AT-2 HIV-1MN (Lots 3808, 3965, 3937, and 3934).
1500ng/10
6 p24 equivalents of HIV-1 was added to the cytokine-
matured DCs on day six and incubated overnight (14–16 hours) at
37
uC and after incubation the DCs were washed.
Priming and Restimulation of T cells
Naı ¨ve CD4
+ and CD8
+ T cells were isolated by negative
selection from frozen PBMCs, using magnetic beads (mb) to
remove monocytes (CD14mb), B cells (CD19mb), NK cells
(CD56mb), and memory T cells (CD45ROmb) (Miltenyi Biotec,
Auburn, CA) and co-cultured with the HIV-pulsed MDDCs at a
1:10 or 1:15 ratio. Priming cultures were restimulated at day 7, 14,
21, and 28 with the addition of autologous HIV-pulsed MDDCs to
the priming cultures.
Measurement of expansion of antigen-specific CD8+ and
CD4+ T cells after 7 days expansion by recall ELISPOT
Mature MDDCs pulsed with microvesicles, AT-2 or infectious
HIV-1 were cultured with autologous bulk T cells at 1:10–1:30
ratios for 7 days. The expanded T cells were harvested and added
to IFN-c ELISPOT plates at 50,000 T cells/well and restimulated
with DCs infected with vaccinia-vectors (MOI=2) (V-ctr, V-env,
V-gag, V-pol, V-nef) or pulsed with control, gp160, nef, p66, or
p24 proteins (5 mg/ml; Protein Sciences Corporation, Meriden,
CT). The ratio of DCs to T cells was 1:10. The ELISPOT assays
were carried out as described above. DCs infected with vaccinia-
vectors were used to monitor CD8+ T cell responses[63] and
HIV-protein pulsed MDDCs were used to monitor CD4+ T cell
responses.
Mapping of Epitopes
Mapping of epitopes was done using pools of overlapping
peptides based on the consensus clade B sequence spanning the
entire HIV proteome (Los Alamos immunology database). The
peptides were mostly 18-mers and overlapped by 10 amino acids.
To facilitate the screening of the peptides, peptide pool matrices
were used in ELISPOT assays as described previously[19].
Reconfirmations of positive wells were done with single peptides.
Assessment of polyfunctionality of primed CD4+ and
CD8+ T cells
Analysis of the capacity of primed CD4+ and CD8+ T cells to
secrete multiple cytokines/chemokines was done by initially
stimulating them with MDDCs pulsed with 1500ng/10
6 p24
equivalents HIV-1 for 6 hours with 10 mg/ml of the intracellular
transport inhibitor brefeldin A (BFA; Sigma) before staining for the
intracellular production of cytokines/chemokines.
Antibodies and flow cytometry
MDDCs were stained with PE-conjugated antibodies to CD80,
CD83, CD86, CD40, CD209, MHC class I and MHC class II
(BD Pharmingen San Jose, CA). Primed T cells were stained with
fluorochrome-conjugated antibodies to CD3, CD4, CD8, and
IFN-c (BD Pharmingen). For the assessment of cytokine/
chemokine production, primed T cells were stained with
fluorochrome-conjugated antibodies to IL-2, TNF, MIP-1b, and
IFN-c (BD Pharmingen). Flow cytometry analysis was performed
on a FACSCalibur or LSRII (BD Biosciences). Data was analyzed
using Cell Quest (BD Biosciences) or FlowJo (Tree Star, Inc,
Ashland, OR) software.
Subjects with acute or recent HIV infection
24 individuals with acute or early HIV-infection were enrolled
in this study. Acute HIV-infection (n=9) was defined by the
presence of HIV-RNA in the plasma, a negative or weakly
positive HIV-antibody by HIV-1/2 ELISA, and the detection of
no more than three bands in an HIV Western blot (n=3); recent
HIV infection was defined by a positive ELISA and confirmed
by detuned negative ELISA or confirmed previously negative
ELISA. All but one of participants had symptoms compatible
with the acute retroviral syndrome and the first blood sample
available for immunological studies (baseline) was drawn at a
median of 12 days (range 5–27) after onset of symptoms. Nine
subjects were treated with HAART after this visit whereas three
remained without antiretroviral therapy. Study participants were
recruited either from the Massachusetts General Hospital and
the Fenway Community Heath Care Center, Boston or via
Center for HIV/AIDS Vaccine Immunology (CHAVI) clinical
sites. All individuals gave written consent to participate, and the
study was approved by the respective institutional review boards
and conducted in accordance with the human experimentation
guidelines.
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